Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition
Authors:
- Olive S. EcksteinOEOlive S. Eckstein
- the NACHO-LIBRE Study GroupTGthe NACHO-LIBRE Study Group
- 11 April 2019
- journal article
- letter
- Published by American Society of Hematology in Blood
- Vol. 133 (15) , 1691-1694
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosisPediatric Blood & Cancer, 2018
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell HistiocytosisJAMA Oncology, 2018
- RAF/MEK/extracellular signal–related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesionsJournal of Experimental Medicine, 2017
- A somatic mutation in erythro-myeloid progenitors causes neurodegenerative diseaseNature, 2017
- Diverse and Targetable Kinase Alterations Drive Histiocytic NeoplasmsCancer Discovery, 2016
- Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 studyBlood, 2015
- Vemurafenib Use in an Infant for High-Risk Langerhans Cell HistiocytosisJAMA Oncology, 2015
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsNew England Journal of Medicine, 2015
- High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosisBlood, 2014
- Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosisBlood, 2013